Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

123.79 +1.18 (+0.96%)
Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
The AI Imperative: Why Rapid Upskilling is Non-Negotiable for Pharma’s Future
The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by... 
Via TokenRing AI
Topics Artificial Intelligence Economy
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
Earnings Scheduled For October 28, 2025
 
Via Benzinga
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis
Via Stocktwits
What to Expect from Novartis's Earnings
 
Via Benzinga
AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine
Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
Novartis is set to boost its developmental pipeline with this acquisition. 
Via The Motley Fool
Here's My Favorite Passive Income Investment
International dividend stocks are finally having their moment after years of underperformance, and this single Vanguard fund captures the opportunity with rock-bottom fees. 
Via The Motley Fool
Topics ETFs
Is the Market Bullish or Bearish on Novartis AG?
 
Via Benzinga
United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short
Shares of United Therapeutics slipped slightly Wednesday on light sales of its bread-and-butter drug, Tyvaso. 
Via Investor's Business Daily
Novartis Slips As Generics Champ At Heart-Failure Drug In Mixed Third Quarter
Generic competition had a 7 percentage-point negative impact on the company's biggest drug. 
Via Investor's Business Daily
Novartis Maintains Outlook Even As Generics Bite Into Profits
Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighed on results. 
Via Benzinga
'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours
U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acquisitions (M&A) are picking up after the tariff-induced cool-off earlier... 
Via Benzinga
Is It Too Late To Buy Avidity Stock After Novartis Deal?
Novartis revealed plans of acquiring Avidity Biosciences Inc. in a $12 billion all-cash transaction. The announcement sent RNA shares soaring roughly 44% on Monday. 
Via Talk Markets
Why Dyne Therapeutics Stock Crushed the Market on Monday
Biotechs like it are clearly valuable to strategic acquirers. 
Via The Motley Fool
Wall Street Soars as Qualcomm Ignites the AI Race
Investor optimism drives the S&P 500 to new records while Qualcomm steals the spotlight with an 11% surge after unveiling new AI chips. 
Via Chartmill
Topics Artificial Intelligence Stocks
Why Avidity Biosciences Stock Blasted 42% Higher Today
If all goes well, the company will be part of a much larger enterprise starting next year. 
Via The Motley Fool
Avidity Biosciences Soars After $72 Per Share Novartis Takeover
Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral. 
Via Benzinga
Qualcomm, Tesla, Intellia Therapeutics, Avidity Biosciences, Dyne Therapeutics: Stocks Making The Biggest Moves Today
Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Via Investor Brand Network
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal
Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash. 
Via Benzinga
Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today
Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share. 
Via Stocktwits
Stock Market Today: Dow Jones, S&P 500 Futures Climb Ahead Of Busy Week On Wall Street—Novartis, Nucor, Waste Management In Focus
U.S. stock futures rose on Monday following Friday’s positive moves. Futures of major benchmark indices were higher. 
Via Benzinga
Topics Stocks
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly... 
Via MarketMinute
Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock
Kratos secured a $68.3 million deal and a contract through the Defense Department's Industrial Base Analysis and Sustainment Program. 
Via Benzinga
AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare
The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence
Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain
Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing significant sustained remission. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.